PlantQuest Facility Insights

AbbVie’s $223M expansion in Singapore is transforming its site into a dual-capability biologics hub

MSD invests $500M in Tuas, boosting next-gen inhaler and vaccine production.

Abbott’s $280M Tuas site is now a smart, sustainable flagship and real-time asset visibility.

SK Biotek invests €35M in a next-gen API facility in Dublin, boosting European capacity.

Pfizer’s Sanford site blends innovation with resilience to drive sterile injectable excellence.

Merck’s $1B Durham site sets a new benchmark for high-capacity, flexible vaccine production.

Fujifilm Diosynth’s Holly Springs expansion doubles biologics capacity.

Grifols’ Clayton site leads in plasma-derived therapies with $400M investment.

Novo Nordisk’s $2B expansion will power next-gen diabetes APIs at a global insulin hub.

Abbott’s €440M Kilkenny facility is now the global hub for FreeStyle Libre 3 sensor production.